Efficient screening for ovarian cancers using a combination of tumor markers CA602 and CA546

International Journal of Gynecological Cancer

Volumn 15, Issue 1, 2005, Pages 37-44

  Saito, M ^a   Aoki, Daisuke ^a   Susumu, N ^a   Suzuki, A ^a   Suzuki, N ^a   Udagawa, Y ^b   Nozawa, S ^a  

^a KEIO UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CA546; CA602; Combination assay; Ovarian cancer; Screening

Indexed keywords

CA 546 ANTIGEN; CA 602 ANTIGEN; DANAZOL; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; ENDOMETRIOSIS; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZATION; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; ENDOMETRIOSIS; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PILOT PROJECTS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 13244266978     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1048-891X.2005.15004.x     Document Type: Article

References (29)

1. The Research Group for Population-based Cancer Registration in Japan. Cancer Incidence in Japan. In: Tominaga S, Oshima A, eds. Cancer Mortality and Morbidity Statistics Japan and the World-1999 (Monograph on Cancer Research no. 47). Tokyo, Japan: Scientific Societies Press, 1999, 83-143.
2. American Cancer Society. Cancer Facts & Figures - 1995. Atlanta: American Cancer Society, 1995.
3. Vital statistics of Japan, Statistics and Information Department, Ministry of Health, Labour and Welfare, 1997.
4. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in Cancer Incidence and Mortality. IARC Sci Publ 1993:1-806.
5. Pavlik EJ, van Nagell JR, DePriest PD et al. Participation in transvaginal ovarian cancer screening: compliance, correlation factors, and costs. Gynecol Oncol 1995;57:395-400.
6. Jacobs I, Davies AP, Bridges J et al. Prevalence screening for ovarian cancer in postmenopausal women by CA125 measurement and ultrasonography. BMJ 1993;306:1030-4.
7. Bourne TH, Whitehead MI, Campbell S, Royston P, Bhan V, Collins WP. Ultrasound screening for familial ovarian cancer. Gynecol Oncol 1991;43:92-7.
8. van Nagell JR, DePriest PD. Early Diagnosis of Epithelial Ovarian Cancer. In: Markman M, Hoskin WJ, eds. Cancer of the Ovary. New York: Raven Press, 1993, 127-31.
9. Jacobs I, Bast RC. The CA125 tumor associated antigen; a review of the literature. Hum Reprod 1989;4:1-12.
10. Nozawa S, Udagawa Y, Sasaki H et al. Studies of clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602 -CA602 assay reagent kit, performance, its normal value and correlations with other tumor markers. Jpn J Cancer Chemo 1992;19:2085-93 (in Japanese).
11. Nozawa S, Yajima M, Sasaki H et al. A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II). Jpn J Cancer Res 1991;82:854-61.
12. Nozawa S, Udagawa Y, Sasaki H et al. A study of preclinical and clinical usefulness of new tumor markers of ovarian carcinoma, CA54/61 and CA602. Evaluation of the diagnostic accuracy of CA54/61, a study of the normal range of its values and its correlation with other tumor markers. Jpn J Cancer Chemo 1992;19:827-35 (in Japanese).
13. Nozawa S, Yajima M, Kojima K et al. Tumor-associated mucin-type glycoprotein (CA54/61) defined by two monoclonal antibodies (MA54 and MA61) in ovarian cancers. Cancer Res 1989;49:493-8.
14. Peterson AJ, Schlom J, Sears HF, Bennett J, Colcher D. A radioimmunoassay for the detection of a human tumor-associated glycoprotein (TAG-72) using monoclonal antibody B72.3. Int J Cancer 1986;37:659-66.
15. Kjeldsen T, Clausen H, Hirohashi S, Ogawa T, Iijima H, Hakomori S. Preparation and characterization of monoclonal antibodies directed to the tumor -associated O-linked sialosyl-2-6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res 1988;48:2214-20.
16. Nozawa S, Aoki D, Yajima M et al. CA54/61 as a marker for epithelial ovarian cancer. Cancer Res 1992;52:1205-59.
17. Bast RC, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
18. Nozawa S. The present and the future of tumor markers. Acta Obst Gynaecol Jpn 1991;43:883-9 (in Japanese).
19. Terajima Y. Ovarian cancer. Acta Obst Gynaecol Jpn 1998;40:N12-5 (in Japanese).
20. Flam F, Einhorn N, Sjovall K. Symptomatology of ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1998;27:53-7.
21. Finn CB, Luesley DM, Buxton EJ et al. Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review. Br J Obstet Gynaecol 1992;99:54-8.
22. Lynch HT, Lynch JF. Hereditary ovarian carcinoma. Hematol Oncol Clin North Am 1992;6:738-811.
23. Heintz AP, Hacker NF, Lagasse LD. Epidemiology and etiology of ovarian cancer: a review. Obstet Gynecol 1985;66:127-35.
24. Takano M, Aida H, Tsuneki I et al. Mutational analysis of BRCA1 gene in ovarian and breast-ovarian cancer families in Japan. Jpn J Cancer Res 1997;88:407-13.
25. Houlston RS, Collins A, Slacks J, Campbell WP, Whitehead MI, Morton NE. Genetic epidemiology of ovarian cancer: segregation analysis. Ann Hum Genet 1991;55:291-9.
26. van Nagell JR, Higgins RV, Donaldson ES et al. Transvaginal sonography as a screening method for ovarian cancer. A report of the first 1000 cases screened. Cancer 1990;65:573-7.
27. DePriest PD, van Nagell JR, Gallion HH et al. Ovarian cancer screening in asymptomatic postmenopausal women. Gynecol Oncol 1993;51:205-9.
28. Kurjak A, Shalan H, Kupesic S et al. An attempt to screen asymptomatic women for ovarian and endometrial cancer with transvaginal color and pulsed Doppler sonography. J Ultrasound Med 1994;13:295-301.
29. Kerber RA, Slattery ML. The impact of family history on ovarian cancer risk. The Utah Population Database. Arch Intern Med 1995;155:905-12.